BioSpace News Archive

Biotech Beach

Adamis Pharmaceuticals Updates Comparative Pharmacology Model Data Supporting the Higher 5 mg Intramuscular Dose of Naloxone in ZIMHI™Drug overdoses are the leading cause of death for those under age 50

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) announced today that additional data in a quantitative systems pharmacology model supports the dose of naloxone hydrochloride that is included in the company’s ZIMHI™ (naloxone HCL Injection, USP) 5 mg/0.5 mL product.

December 1, 2021
·
9 min read
Business

Arch Therapeutics Adds Key Opinion Leader Interview on Diabetic Foot Ulcers to the Experts in Wound Care Program

Arch Therapeutics, Inc. announced today that it has added a key opinion leader (KOL) interview to its Experts in Wound Care Program, a series of interviews with key opinion leaders dedicated to advancing wound care.

December 1, 2021
·
4 min read
Business

Indaptus Therapeutics Appoints Mark Gilbert, M.D., to Board of DirectorsFormer Chief Medical Officer of Juno Therapeutics Brings Decades of Oncology Clinical Development Expertise

Indaptus Therapeutics, Inc., announces the appointment of Mark Gilbert, M.D., to its Board of Directors.

December 1, 2021
·
5 min read
Insightec Announces FDA Clearance For Exablate Prostate To Treat Prostate Tissue

Insightec, a global healthcare company creating the next generation of patient care by realizing the therapeutic power of acoustic energy, announced today that the Exablate Prostate system received FDA 510K clearance for treating prostate tissue with high intensity Focused Ultrasound.

December 1, 2021
·
3 min read
Pharm Country

Peptilogics Announces Two Peer-Reviewed Publications on Designed Peptide Therapeutic PLG0206 for Periprosthetic Joint Infection

Peptilogics today announced two studies on its lead designed peptide therapeutic, PLG0206, an investigational drug, have been published in peer-reviewed journals Antimicrobial Agents and Chemotherapy (AAC) and Microbiology Spectrum.

December 1, 2021
·
4 min read
Drug Development

Edesa Biotech Marks Enrollment Milestone in Dermatitis Study

Edesa Biotech, Inc. today announced that it has completed enrollment of more than 75% of the patients planned for the primary cohort of a Phase 2b clinical study evaluating the company’s drug candidate, designated EB01, as a monotherapy for chronic allergic contact dermatitis.

December 1, 2021
·
8 min read
Eurofins Environment Testing Launches PFAS Exposure™ Self-Collection Blood Test

Eurofins Environment Testing Launches PFAS Exposure™ Self-Collection Blood Test.

December 1, 2021
·
2 min read
Pharm Country

Teva Announces Launch of an Authorized Generic of Epiduo® Forte Gel (adapalene and benzoyl peroxide gel 0.3%/2.5%), in the U.S.

Teva Pharmaceuticals today announced the launch of an authorized generic of Epiduo® 1 Forte Gel (adapalene and benzoyl peroxide gel 0.3%/2.5%), in the United States.

December 1, 2021
·
7 min read
Business

Premas Biotech and Oravax Medical to Test Their Triple Antigen Oral Vaccine Candidate Against Omicron Variant of Concern

Premas Biotech announced today that its joint venture Oravax will initiate testing of their oral virus-like particle (VLP) vaccine candidate against Omicron variant of SARS-CoV 2 virus through preclinical, in vitro and challenge studies to assess its efficacy for the new mutant strain.

December 1, 2021
·
2 min read
Business

Sobi and Selecta Biosciences announce completion of enrolment in DISSOLVE Phase 3 study evaluating SEL-212 for chronic refractory gout

Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO: SOBI) and Selecta Biosciences, Inc. (NASDAQ: SELB), today announced the completion of enrolment for DISSOLVE I, the first of two clinical studies of the phase 3 DISSOLVE development programme of SEL-212 for chronic refractory gout.

December 1, 2021
·
5 min read